GlassScriptPhysician profile
John A Burnett
NPI 1235302399
$4,386.88
in general payments reported to CMS, 2019-2025
20 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $681 · 2021: $685 · 2022: $693 · 2023: $744 · 2024: $549 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $756.99 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $475.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $474.18 | 2020-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $431.06 | 2020-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $418.00 | 2019-2024 | Jornay Pm |
| Lundbeck LLC | $402.53 | 2019-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $297.64 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $246.94 | 2019-2022 | |
| Alkermes, INC. | $233.85 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $168.38 | 2020-2023 | |
| Corium, LLC | $135.14 | 2022-2024 | Azstarys, Azstarys |
| Abbvie INC. | $85.09 | 2021-2025 | Vraylar |
| Idorsia Pharmaceuticals US INC | $66.41 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $41.08 | 2025 | Jornay Pm |
| Tris Pharma INC | $38.39 | 2024-2025 | Dyanavel Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $36.77 | 2020 | |
| Shire North American Group INC | $23.10 | 2019 | |
| Axsome Therapeutics, INC. | $20.89 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $20.88 | 2024 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.